Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1997 2
1999 1
2001 4
2002 8
2003 1
2004 6
2005 12
2006 8
2007 7
2008 5
2009 15
2010 12
2011 14
2012 16
2013 18
2014 12
2015 11
2016 4
2017 5
2019 1
2020 2
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 23573520

149 results

Results by year

Filters applied: . Clear all
Page 1
[Analysis of drug therapy of lung cancer in Hungary].
Moldvay J, Rokszin G, Abonyi-Tóth Z, Katona L, Kovács G. Moldvay J, et al. Magy Onkol. 2013 Mar;57(1):33-8. Epub 2012 Dec 20. Magy Onkol. 2013. PMID: 23573520 Free article. Hungarian.
Lung cancer drug therapy in Hungary - 3-year experience.
Moldvay J, Rokszin G, Abonyi-Tóth Z, Katona L, Fábián K, Kovács G. Moldvay J, et al. Onco Targets Ther. 2015 May 13;8:1031-8. doi: 10.2147/OTT.S65794. eCollection 2015. Onco Targets Ther. 2015. PMID: 25999737 Free PMC article.
Perspectives on salvage therapy for non-small-cell lung cancer.
Cappuzzo F, Finocchiaro G, Trisolini R, Toschi L, Bartolini S, Metro G, Crinò L. Cappuzzo F, et al. Oncology (Williston Park). 2005 Jul;19(8):989-95; discussion 995-6, 999, 1003-4, passim. Oncology (Williston Park). 2005. PMID: 16131043 Review.
Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Bylicki O, Ferlay C, Chouaid C, Lavolé A, Barlési F, Dubos C, Westeel V, Créquit J, Corre R, Vergnenègre A, Monnet I, Le Caer H, Fournel P, Vaylet F, Falchero L, Poudenx M, Linard P, Pérol D, Zalcman G, Pérol M. Bylicki O, et al. J Thorac Oncol. 2013 Jul;8(7):906-14. doi: 10.1097/JTO.0b013e31828cb505. J Thorac Oncol. 2013. PMID: 23591160 Free article. Clinical Trial.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Rosell R, et al. Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26. Lancet Oncol. 2012. PMID: 22285168 Clinical Trial.
149 results